Zhang Xie, Sun Chao-Yue, Zhang Yong-Bin, Guo Hui-Zhen, Feng Xue-Xuan, Peng Shao-Zhong, Yuan Jie, Zheng Rong-Bo, Chen Wei-Ping, Su Zi-Ren, Huang Xiao-Dan
School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China; Guangdong Provincial Key Laboratory of New Chinese Medicinal Development and Research, Guangzhou 510006, PR China.
School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China.
J Ethnopharmacol. 2016 Jun 20;186:91-102. doi: 10.1016/j.jep.2016.03.057. Epub 2016 Mar 30.
Kegan Liyan oral liquid (KGLY), a Chinese prescription modified from classic formulas Yin-Qiao-San (from TCM classic Wenbing Tiaobian) and Shen-Jie-San (first mentioned in Shanghan Wenyi Tiaobian), has been reported to exert heat-clearing and detoxifying effects and used extensively for the treatment of severe pulmonary diseases in clinics including influenza, cough and pneumonia.
The purpose of this study was to investigate the protective effect of KGLY on lipopolysaccharide (LPS) induced acute lung injury (ALI) in mice and to illuminate the underlying mechanisms.
Mice were orally administrated with KGLY (50, 100 and 150mg/kg) before intratracheal instillation of LPS. 24h post LPS challenge, lung tissues and the bronchoalveolar lavage fluid (BALF) were collected for lung wet/dry (W/D) weight ratio, histopathological examinations and biochemical analyses. The cell counts, protein concentration, interleukin-1β (IL-1β), interleukin-6 (IL-6), necrosis factor-α (TNF-α), macrophage inflammatory protein-2 (MIP-2) in BALF, superoxide dismutase (SOD), glutathione (GSH), myeloperoxidase (MPO) and malondialdehyde (MDA) levels were detected. Meanwhile, the activation of toll-like receptor 4 (TLR4), nuclear factor kappa B (NF-κB), as well as matrix metalloproteinases 9 (MMP-9) were determined by western blot assay.
KGLY significantly prolonged mice survival time and ameliorated LPS-induced edema, thickening of alveolar septa and inflammatory cell infiltration in a dose-dependent manner. Additionally, KGLY markedly attenuated LPS-induced acute pulmonary inflammation via decreasing the expressions of cytokines and chemokines (IL-1β, IL-6, TNF-α, and MIP-2), enhanced the activities of anti-oxidative indicators (SOD and GSH), suppressed the levels of MPO and MDA, and down-regulated the expressions of TLR4, NF-κB and MMP9.
The results suggested that the relieving effect of KGLY against LPS-induced ALI might be partially due to suppression of oxidative stress and inflammatory response, inhibition of TLR4-mediated NF-κB activation, and down-regulation of MMP9 expression, indicating it may be a potential therapeutic agent for ALI.
克感利咽口服液(KGLY)是一种源自经典方剂银翘散(出自中医经典《温病条辨》)和神解汤(首载于《伤寒温疫条辨》)的中药制剂,据报道具有清热排毒作用,在临床上广泛用于治疗包括流感、咳嗽和肺炎在内的严重肺部疾病。
本研究旨在探讨克感利咽口服液对脂多糖(LPS)诱导的小鼠急性肺损伤(ALI)的保护作用,并阐明其潜在机制。
在气管内滴注LPS前,给小鼠口服克感利咽口服液(50、100和150mg/kg)。LPS攻击后24小时,收集肺组织和支气管肺泡灌洗液(BALF),用于检测肺湿/干(W/D)重量比、组织病理学检查和生化分析。检测BALF中的细胞计数、蛋白质浓度、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、巨噬细胞炎性蛋白-2(MIP-2),以及超氧化物歧化酶(SOD)、谷胱甘肽(GSH)、髓过氧化物酶(MPO)和丙二醛(MDA)水平。同时,通过蛋白质印迹法检测Toll样受体4(TLR4)、核因子κB(NF-κB)以及基质金属蛋白酶9(MMP-9)的激活情况。
克感利咽口服液显著延长小鼠存活时间,并以剂量依赖性方式改善LPS诱导的水肿、肺泡间隔增厚和炎性细胞浸润。此外,克感利咽口服液通过降低细胞因子和趋化因子(IL-1β、IL-6、TNF-α和MIP-2)的表达,显著减轻LPS诱导的急性肺部炎症,增强抗氧化指标(SOD和GSH)的活性,抑制MPO和MDA水平,并下调TLR4、NF-κB和MMP9的表达。
结果表明,克感利咽口服液对LPS诱导的ALI的缓解作用可能部分归因于抑制氧化应激和炎症反应、抑制TLR4介导的NF-κB激活以及下调MMP9表达,表明其可能是ALI的一种潜在治疗药物。